Anand SS - Search Results

1

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Moayyedi P, et al. Among authors: anand ss. Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29. Gastroenterology. 2019. PMID: 31152740 Clinical Trial.

2

Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies.

Avezum A Jr, Pais P, Flather MD, Anand S, Yusuf S. Avezum A Jr, et al. Indian Heart J. 1995 Mar-Apr;47(2):95-105. Indian Heart J. 1995. PMID: 7590849 Review. No abstract available.

3

Cost of prevention. The case of lipid lowering.

Yusuf S, Anand S. Yusuf S, et al. Circulation. 1996 May 15;93(10):1774-6. doi: 10.1161/01.cir.93.10.1774. Circulation. 1996. PMID: 8635252 No abstract available.

4

Treatment for acute myocardial infarction. Overview of randomized clinical trials.

Yusuf S, Anand S, Avezum A Jr, Flather M, Coutinho M. Yusuf S, et al. Eur Heart J. 1996 Dec;17 Suppl F:16-29. doi: 10.1093/eurheartj/17.suppl_f.16. Eur Heart J. 1996. PMID: 8960444 Review.

5

Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths.

Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Sheth T, et al. CMAJ. 1999 Jul 27;161(2):132-8. CMAJ. 1999. PMID: 10439820 Free PMC article.

6

Cardiovascular diseases in ethnic groups.

Anand S, Yusuf S. Anand S, et al. Can J Cardiol. 1999 Dec;15 Suppl G:47G-50G. Can J Cardiol. 1999. PMID: 10692658 No abstract available.

7

The impending global epidemic of cardiovascular diseases.

Ounpuu S, Anand S, Yusuf S. Ounpuu S, et al. Eur Heart J. 2000 Jun;21(11):880-3. doi: 10.1053/euhj.1999.1880. Eur Heart J. 2000. PMID: 10806010 No abstract available.

8

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

Yusuf S, Reddy S, Ounpuu S, Anand S. Yusuf S, et al. Circulation. 2001 Nov 27;104(22):2746-53. doi: 10.1161/hc4601.099487. Circulation. 2001. PMID: 11723030 Review.

9

Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies.

Yusuf S, Reddy S, Ounpuu S, Anand S. Yusuf S, et al. Circulation. 2001 Dec 4;104(23):2855-64. doi: 10.1161/hc4701.099488. Circulation. 2001. PMID: 11733407

10

Diagnostic strategies to detect glucose intolerance in a multiethnic population.

Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q, Teo KK, Yusuf S. Anand SS, et al. Diabetes Care. 2003 Feb;26(2):290-6. doi: 10.2337/diacare.26.2.290. Diabetes Care. 2003. PMID: 12547851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

468 results

Search Page